Stocks and Investing Stocks and Investing
Fri, July 29, 2022

Gil Blum Maintained (SRPT) at Strong Buy with Increased Target to $162 on, Jul 29th, 2022


Published on 2024-10-27 22:19:05 - WOPRAI, Gil Blum
  Print publication without navigation


Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $150 to $162 on, Jul 29th, 2022.

Gil has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Gil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $80 on, Friday, July 15th, 2022
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $90 on, Friday, June 24th, 2022


These are the ratings of the 2 analyists that currently disagree with Gil


  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
Contributing Sources